NAII filing — read by section

Item 8. Financial Statements and Supplementary Data

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 

 Report of Independent Registered Public Accounting Firm 

 To the Board of Directors and
 Stockholders of Natural Alternatives International, Inc.

 Opinion on the Consolidated Financial Statements 

 We have audited the accompanying consolidated balance sheets of Natural Alternatives International, Inc. (the “Company”) as of June 30, 2024 and 2023, and the related consolidated statements of operations and comprehensive (loss) income, stockholders’ equity and cash flows for each of the two years in the period ended June 30, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of June 30, 2024 and 2023, and the consolidated results of its operations and its cash flows for each of the two years in the period ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America.

 Basis for Opinion 

 These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 Critical Audit Matter 

 The critical audit matter communicated below is a matter arising from the current-period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of this critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 Revenue Recognition — Refer to Note A to the Consolidated Financial Statements 

 Critical Audit Matter Description 

 The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products. The Company is a party to certain customer supply contracts that contain unique, customer-specific terms and conditions that result in variable consideration. For such contracts, significant interpretation may be required to determine the contract terms, estimated amounts and timing of recognition of variable consideration. Variable consideration includes volume-related and other discounts and pricing concessions.

 Our assessment of management’s evaluation of the above referenced matter related to proper revenue recognition is significant to our audit because the amounts may potentially be material to the consolidated financial statements, the assessment process involves significant judgment, and the application of U.S. generally accepted accounting principles in this area is complex.

 24
 
 Table of Contents 
 
 How the Critical Audit Matter Was Addressed in the Audit 

 Our principal audit procedures related to the Company’s revenue recognition for customer contracts that include variable consideration included the following:

 ●
 We evaluated the appropriateness of management’s revenue recognition policies.
 
 ●
 We tested the mathematical accuracy of management’s calculations of revenue, including variable consideration, and the associated timing of revenue recognized in the consolidated financial statements.
 
 ●
 We identified customer contracts with variable consideration and performed the following procedures:
 
 o
 Obtained and read contracts and other source documents for each selection.
 
 o
 Tested management’s identification and treatment of the key contract terms, including performance obligations and variable consideration.
 
 o
 Evaluated the appropriateness of management's application of the Company’s accounting policies, along with their use of estimates, in the determination of revenue recognition in the proper amounts.
 
 /s/ HASKELL & WHITE LLP 

 We have served as the Company’s auditor since 2014.

 Irvine, California 

 September 27, 2024

 25
 
 Table of Contents 
 
 Natural Alternatives International, Inc. 

 Consolidated Balance Sheets 

 As of June 30 

 (Dollars in thousands, except share and per share data) 

 2024 
 2023 
 
 Assets 
 
 Current assets:
 
 Cash and cash equivalents
 $ 11,981 $ 13,604 

 Accounts receivable – less allowance for credit losses of $ 0 at June 30, 2024 and $ 23 at June 30, 2023
 16,891 7,022 

 Inventories, net
 24,249 29,694 

 Income tax receivable
 — 305 

 Forward contracts
 492 390 

 Prepaids and other current assets
 7,997 5,995 

 Total current assets
 61,610 57,010 

 Property and equipment, net
 52,211 53,841 

 Operating lease right-of-use assets
 43,537 20,369 

 Deferred tax asset, net – noncurrent
 3,170 355 

 Other noncurrent assets, net
 1,814 2,577 

 Total assets
 $ 162,342 $ 134,152 

 Liabilities and Stockholders’ Equity 
 
 Current liabilities:
 
 Accounts payable
 $ 12,740 $ 7,778 

 Accrued liabilities
 2,847 2,409 

 Accrued compensation and employee benefits
 2,090 2,246 

 Customer deposits
 302 317 

 Short-term liability – operating leases
 1,194 2,448 

 Forward contracts
 91 — 

 Income taxes payable
 505 374 

 Mortgage note payable, current portion
 296 312 

 Line of credit – current
 3,400 — 

 Total current liabilities
 23,465 15,884 

 Long-term liability – operating leases
 46,468 18,965 

 Long-term pension liability
 141 339 

 Mortgage note payable, net of current portion
 8,933 9,205 

 Income taxes payable, noncurrent
 740 987 

 Total liabilities
 79,747 45,380 

 Commitments and contingencies (Notes D, F, H, J and M)
 
 Stockholders’ equity:
 
 Preferred stock; $ .01 par value; 500,000 shares authorized; none issued or outstanding
 — — 

 Common stock; $ .01 par value; 20,000,000 shares authorized at June 30, 2024 and June 30, 2023, issued and outstanding (net of treasury shares) 6,200,185 at June 30, 2024 and 6,073,813 at June 30, 2023
 93 91 

 Additional paid-in capital
 32,634 31,436 

 Retained earnings
 72,966 80,183 

 Treasury stock, at cost, 3,280,721 shares at June 30, 2024 and 3,240,593 at June 30, 2023
 ( 23,076 ) ( 22,855 ) 

 Accumulated other comprehensive loss
 ( 22 ) ( 83 ) 

 Total stockholders’ equity
 82,595 88,772 

 Total liabilities and stockholders’ equity
 $ 162,342 $ 134,152 

 See accompanying notes to consolidated financial statements. 

 26
 
 Table of Contents 
 
 Natural Alternatives International, Inc. 

 Consolidated Statements of Operations and Comprehensive (Loss) Income 

 For the Years Ended June 30 

 (Dollars in thousands, except share and per share data) 

 2024 
 
 2023 
 
 Net sales
 
 $ 
 113,796 
 
 $ 
 154,015 
 
 Cost of goods sold
 
 106,931 
 
 135,857 
 
 Gross profit
 
 6,865 
 
 18,158 
 
 Selling, general and administrative expenses
 
 15,399 
 
 14,869 
 
 Recoveries of uncollectible accounts receivable
 
 — 
 
 ( 1,424 
 ) 
 
 (Loss) income from operations
 
 ( 8,534 
 ) 
 
 4,713 
 
 Other income (expense):
 
 Interest income
 
 176 
 
 33 
 
 Interest expense
 
 ( 361 
 ) 
 
 ( 451 
 ) 
 
 Foreign exchange loss
 
 ( 652 
 ) 
 
 ( 658 
 ) 
 
 Other, net
 
 ( 93 
 ) 
 
 ( 82 
 ) 
 
 Total other expense
 
 ( 930 
 ) 
 
 ( 1,158 
 ) 
 
 (Loss) income before income taxes
 
 ( 9,464 
 ) 
 
 3,555 
 
 (Benefit) provision for income taxes
 
 ( 2,247 
 ) 
 
 1,033 
 
 Net (loss) income
 
 $ 
 ( 7,217 
 ) 
 
 $ 
 2,522 
 
 Change in minimum pension liability, net of tax
 
 $ 
 102 
 
 $ 
 64 
 
 Unrealized loss resulting from change in fair value of derivative instruments, net of tax
 
 ( 41 
 ) 
 
 ( 1,846 
 ) 
 
 Comprehensive (loss) income
 
 $ 
 ( 7,156 
 ) 
 
 $ 
 740 
 
 Net (loss) income per common share:
 
 Basic
 
 $ 
 ( 1.23 
 ) 
 
 $ 
 0.43 
 
 Diluted
 
 $ 
 ( 1.23 
 ) 
 
 $ 
 0.43 
 
 Weighted average common shares outstanding:
 
 Basic
 
 5,870,974 
 
 5,863,083 
 
 Diluted
 
 5,870,974 
 
 5,877,559 
 
 See accompanying notes to consolidated financial statements. 

 27
 
 Table of Contents 
 
 Natural Alternatives International, Inc. 

 Consolidated Statements of Stockholders ’ Equity 

 For the Years Ended June 30 

 (Dollars in thousands) 

 Accumulated 
 
 Additional 
 
 Other 
 
 Common Stock 
 
 Paid-in 
 
 Retained 
 
 Treasury Stock 
 
 Comprehensive 
 
 Shares 
 
 Amount 
 
 Capital 
 
 Earnings 
 
 Shares 
 
 Amount 
 
 Income (Loss) 
 
 Total 
 
 Balance, June 30, 2022
 
 9,191,406 
 
 $ 
 89 
 
 $ 
 30,423 
 
 $ 
 77,661 
 
 3,061,795 
 
 $ 
 ( 21,352 
 ) 
 
 $ 
 1,699 
 
 $ 
 88,520 
 
 Issuance of common stock for restricted stock grants
 
 123,000 
 
 2 
 
 ( 2 
 ) 
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 Compensation expense related to stock compensation plans
 
 — 
 
 — 
 
 1,015 
 
 — 
 
 — 
 
 — 
 
 — 
 
 1,015 
 
 Repurchase of common stock
 
 — 
 
 — 
 
 — 
 
 — 
 
 164,399 
 
 ( 1,503 
 ) 
 
 — 
 
 ( 1,503 
 ) 
 
 Forfeiture of restricted stock
 
 — 
 
 — 
 
 — 
 
 — 
 
 14,399 
 
 — 
 
 — 
 
 — 
 
 Change in minimum pension liability, net of tax
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 64 
 
 64 
 
 Unrealized loss resulting from change in fair value of derivative instruments, net of tax
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 ( 1,846 
 ) 
 
 ( 1,846 
 ) 
 
 Net income
 
 — 
 
 — 
 
 — 
 
 2,522 
 
 — 
 
 — 
 
 — 
 
 2,522 
 
 Balance, June 30, 2023
 
 9,314,406 
 
 $ 
 91 
 
 $ 
 31,436 
 
 $ 
 80,183 
 
 3,240,593 
 
 $ 
 ( 22,855 
 ) 
 
 $ 
 ( 83 
 ) 
 
 $ 
 88,772 
 
 Issuance of common stock for restricted stock grants
 
 166,500 
 
 2 
 
 ( 2 
 ) 
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 Compensation expense related to stock compensation plans
 
 — 
 
 — 
 
 1,200 
 
 — 
 
 — 
 
 — 
 
 — 
 
 1,200 
 
 Repurchase of common stock
 
 — 
 
 — 
 
 — 
 
 — 
 
 37,128 
 
 ( 221 
 ) 
 
 — 
 
 ( 221 
 ) 
 
 Forfeiture of restricted stock
 
 — 
 
 — 
 
 — 
 
 — 
 
 3,000 
 
 — 
 
 — 
 
 — 
 
 Change in minimum pension liability, net of tax
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 102 
 
 102 
 
 Unrealized loss resulting from change in fair value of derivative instruments, net of tax
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 — 
 
 ( 41 
 ) 
 
 ( 41 
 ) 
 
 Net loss
 
 — 
 
 — 
 
 — 
 
 ( 7,217 
 ) 
 
 — 
 
 — 
 
 — 
 
 ( 7,217 
 ) 
 
 Balance, June 30, 2024
 
 9,480,906 
 
 $ 
 93 
 
 $ 
 32,634 
 
 $ 
 72,966 
 
 3,280,721 
 
 $ 
 ( 23,076 
 ) 
 
 $ 
 ( 22 
 ) 
 
 $ 
 82,595 
 
 See accompanying notes to consolidated financial statements. 

 28
 
 Table of Contents 
 
 Natural Alternatives International, Inc. 

 Consolidated Statements of Cash Flows 

 For the Years Ended June 30 

 (in thousands) 

 2024 
 
 2023 
 
 Cash flows from operating activities 
 
 Net (loss) income
 
 $ 
 ( 7,217 
 ) 
 
 $ 
 2,522 
 
 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
 
 Recoveries of uncollectible accounts receivable
 
 — 
 
 ( 1,424 
 ) 
 
 Depreciation and amortization
 
 4,647 
 
 4,250 
 
 Deferred income taxes
 
 ( 2,907 
 ) 
 
 ( 974 
 ) 
 
 Non-cash lease expenses
 
 6,083 
 
 2,831 
 
 Non-cash compensation
 
 1,200 
 
 1,015 
 
 Pension expense, net of contributions
 
 46 
 
 81 
 
 Gain on disposal of assets
 
 — 
 
 ( 51 
 ) 
 
 Changes in operating assets and liabilities:
 
 Accounts receivable
 
 ( 9,869 
 ) 
 
 11,823 
 
 Inventories
 
 5,445 
 
 2,781 
 
 Operating lease liabilities
 
 ( 3,003 
 ) 
 
 ( 2,134 
 ) 
 
 Prepaids and other assets
 
 ( 1,597 
 ) 
 
 ( 4,362 
 ) 
 
 Accounts payable and accrued liabilities
 
 5,387 
 
 ( 8,606 
 ) 
 
 Forward contracts
 
 372 
 
 863 
 
 Income taxes
 
 189 
 
 ( 169 
 ) 
 
 Accrued compensation and employee benefits
 
 ( 273 
 ) 
 
 ( 1,427 
 ) 
 
 Net cash (used in) provided by operating activities
 
 ( 1,497 
 ) 
 
 7,019 
 
 Cash flows from investing activities 
 
 Purchases of property and equipment
 
 ( 3,017 
 ) 
 
 ( 13,524 
 ) 
 
 Proceeds from sale of property and equipment
 
 — 
 
 57 
 
 Net cash used in investing activities
 
 ( 3,017 
 ) 
 
 ( 13,467 
 ) 
 
 Cash flows from financing activities 
 
 Borrowings on line of credit
 
 3,400 
 
 — 
 
 Repurchase of common stock
 
 ( 221 
 ) 
 
 ( 1,503 
 ) 
 
 Payments on long-term debt
 
 ( 288 
 ) 
 
 ( 278 
 ) 
 
 Net cash provided by (used in) financing activities
 
 2,891 
 
 ( 1,781 
 ) 
 
 Net decrease in cash and cash equivalents
 
 ( 1,623 
 ) 
 
 ( 8,229 
 ) 
 
 Cash and cash equivalents at beginning of year
 
 13,604 
 
 21,833 
 
 Cash and cash equivalents at end of year
 
 $ 
 11,981 
 
 $ 
 13,604 
 
 Supplemental disclosures of cash flow information 
 
 Cash paid during the year for:
 
 Income taxes
 
 $ 
 463 
 
 $ 
 1,842 
 
 Interest
 
 $ 
 285 
 
 $ 
 802 
 
 See accompanying notes to consolidated financial statements. 

 29
 
 Table of Contents 
 
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

 A. Organization and Summary of Significant Accounting Policies 

 Organization 

 We provide private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbs, and other nutritional supplements, as well as other health care products, to consumers both within and outside the U.S. We also seek to commercialize our patent and trademark estate related to the ingredient known as beta-alanine sold under our CarnoSyn®, SR CarnoSyn® trademarks, and recently announced TriBsyn™ tradename through direct raw material sales and various license and similar arrangements.

 Subsidiaries 

 On January 22, 1999, Natural Alternatives International Europe S.A., a Swiss Corporation (NAIE) was formed as our wholly-owned subsidiary, based in Manno, Switzerland. In September 1999, NAIE opened a manufacturing facility and currently possesses manufacturing capability in encapsulation, powders, tablets, finished goods packaging, quality control laboratory testing, warehousing, distribution and administration.

 Principles of Consolidation 

 The consolidated financial statements include the accounts of Natural Alternatives International, Inc. (NAI) and our wholly-owned subsidiary, NAIE. All intercompany accounts and transactions have been eliminated. The functional currency of NAIE, our foreign subsidiary, is the U.S. Dollar. Certain accounts of NAIE have been translated at either current or historical exchange rates, as appropriate, with gains and losses included in the consolidated statements of operations.

 Recently Adopted Accounting Pronouncements 

 In June 2016, the FASB issued ASU 2016 - 13, “Financial Instruments—Credit Losses (Topic 326 ): Measurement of Credit Losses on Financial Instruments.” ASU 2016 - 13 introduced a novel approach to assessing impairments known as the "current expected credit loss model" or "CECL." Unlike the previous standard, which focused on incurred losses, CECL centers on anticipated losses. Under this framework, organizations are obligated to acknowledge an allowance corresponding to their estimate of expected credit losses. The CECL model is applicable to a wide range of financial instruments, including debt instruments, trade receivables, lease receivables, financial guarantee contracts, and other loan commitments. We adopted ASU 2016 - 13 effective July 1, 2023. The adoption of ASU 2016 - 13 did not materially impact our results of operations or our financial statement presentation or related disclosures.

 Recently Issued Accounting and Regulatory Pronouncements 

 In October 2023, the FASB issued Accounting Standards Update ("ASU") 2023 - 06, "Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative". ASU 2023 - 06 clarifies or improves disclosure and presentation requirements on various disclosure areas, including the statement of cash flows, earnings per share, debt, equity, and derivatives. The amendments will align the requirements in the FASB Accounting Standards Codification (ASC) with the SEC’s regulations. The amendments in this ASU will be effective on the date the related disclosures are removed from Regulation S- X or Regulation S-K by the SEC, and will not be effective if the SEC has not removed the applicable disclosure requirement by June 30, 2027. Early adoption is prohibited. As we are currently subject to these SEC requirements, this ASU is not expected to have a material impact on our Consolidated Financial Statements or related disclosures.

 In November 2023, the FASB issued ASU 2023 - 07, "Segment Reporting (Topic 280 ): Improvements to Reportable Segment Disclosures". This amendment improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments in ASU 2023 - 07 are effective for fiscal years beginning after December 15, 2023, with early adoption permitted. This ASU will be adopted in our fiscal 2025. We are currently evaluating the impact of this standard; however, we do not expect it to have a material impact on our Consolidated Financial Statements.

 In December 2023, the FASB issued ASU 2023 - 09, "Income Taxes (Topic 740 ): Improvements to Income Tax Disclosures". The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023 - 09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU will be adopted in our first quarter of fiscal 2026. We are currently evaluating the impact of this standard; however, we do not expect it to have a material impact on our Consolidated Financial Statements.

 In March 2024, the SEC adopted rules under SEC Release No. 33 - 11275, "The Enhancement and Standardization of Climate-Related Disclosures for Investors", which require a registrant to disclose information in annual reports and registration statements about climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition. The information would include disclosure of a registrant's greenhouse gas emissions. In addition, certain disclosures related to severe weather events and other natural conditions will be required in a registrant’s audited financial statements. Annual disclosure requirements would be effective for the Company as early as the fiscal year beginning July 1, 2027. However, in April 2024, the SEC voluntarily stayed the final rules pending certain legal challenges. It is presently unclear what the nature and scope of these requirements may be when and if the stay is lifted. We are evaluating the impact these anticipated types of rules may have on our record keeping and disclosures.

 30 
 
 Table of Contents 
 
 Employee Retention Tax Credit 

 In March 2020, the Coronavirus Aid, Relief, and Economic Security Act was signed into law, providing numerous tax provisions and other stimulus measures, including the Employee Retention Tax Credit (“ERTC”). The Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Rescue Plan Act of 2021 extended the availability of the ERTC. Under these expanded measures, we determined during fiscal 2023 that we qualified for the ERTC for the first three quarters of calendar 2021 and filed amended payroll tax returns that are expected to result in a net refund of $ 3.5 million. Although we don’t anticipate receiving the funds related to these amended returns until sometime in fiscal 2025, we recorded a receivable and recognized a benefit for this amount in our Consolidated Statements of Operations and Comprehensive Income in fiscal 2023 by applying the loss recovery model as codified by Accounting Standards Codification (“ASC”) section 450 “Contingencies” that indicates that an asset related to a recovery should be recognized when the recovery is determined to be probable. We recorded this benefit as a reduction to our payroll tax expense in the fiscal year 2023 with $ 2.2 million of the benefit offsetting cost of goods sold and $ 1.3 million offsetting selling, general and administrative expenses.

 Cash and Cash Equivalents 

 We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

 Fair Value of Financial Instruments 

 Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We use a three -level hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available under the circumstances.

 The fair value hierarchy is broken down into three levels based on the source of inputs. In general, fair values determined by Level 1 inputs use quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access. We classify cash, cash equivalents, and marketable securities balances as Level 1 assets. The approximate fair value of cash and cash equivalents, accounts receivable, accounts payable and short-term borrowings is equal to book value due to the short-term nature of these items. Fair values determined by Level 2 inputs are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable or can be corroborated, either directly or indirectly by observable market data. Level 3 inputs are unobservable inputs for the asset or liability and include situations where there is little, if any, market activity for the asset or liability. These include certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

 Except for cash and cash equivalents, as of June 30, 2024 and June 30, 2023 , we did not have any financial assets or liabilities classified as Level 1. We classify derivative forward exchange contracts as Level 2 assets and liabilities. The fair values were determined by obtaining pricing from our bank.

 Fair value of derivative instruments classified as Level 2 assets and liabilities consisted of the following (in thousands):

 June 30, 
 June 30, 
 
 2024 
 2023 
 
 Interest Swap – Other Current Assets
 $ 111 $ — 

 Euro Forward Contract– Current Assets
 492 250 

 Swiss Franc Forward Contract – Current Assets
 — 140 

 Total Derivative Contracts – Current Assets
 603 390 

 Interest Swap – Other Noncurrent Assets
 — 532 

 Euro Forward Contract– Other Noncurrent Assets
 78 15 

 Total Derivative Contracts – Other Noncurrent Assets
 78 547 

 Swiss Franc Forward Contract – Current Liabilities
 ( 91 ) — 

 Total Derivative Contracts – Current Liabilities
 ( 91 ) — 

 Fair Value Net Asset – all Derivative Contracts
 $ 590 $ 937 

 We also classify any outstanding line of credit and term loan balance as a Level 2 liability, as the fair value is based on inputs that can be derived from information available in publicly quoted markets. As of June 30, 2024, we had $ 3.4 million outstanding on our line of credit and $ 9.2 million outstanding on our term loan. As of June 30, 2023, we had no balance outstanding on our line of credit and $ 9.5 million outstanding on our term loan. As of June 30, 2024 , and June 30, 2023 , we did not have any financial assets or liabilities classified as Level 3. We did not transfer any assets or liabilities between these levels during fiscal 2023 or fiscal 2024 . 

 31 
 
 Table of Contents 
 
 Accounts Receivable 

 We perform ongoing credit evaluations of our customers and adjust credit limits based on payment history and expected future customer credit-worthiness. An allowance for estimated credit losses is maintained based on, but not limited to, historical collection experience, current customer financial condition, current and future economic and market conditions, and age of receivables to identify any customer credit issues. We monitor our expected collections regularly and adjust the allowance for credit loss accounts as necessary to recognize any changes in credit exposure. Upon conclusion that a receivable is uncollectible, we record the respective amount as a charge against allowance for credit losses. To date, such credit loss reserves, in the aggregate, have been adequate to cover collection losses.

 In December 2022, we entered into an agreement to settle the remaining outstanding balance with a former customer whose accounts receivable balance was fully reserved in March 2020. As of the date of the agreement, the remaining amount due from this customer was $ 3.4 million dollars and as part of the settlement, we agreed to a reduced amount of $ 1.4 million. This reduced amount was paid based on an agreed upon payment schedule and if all payments are made as agreed the entire balance will be considered paid in full. As of June 30, 2023, the former customer had made all scheduled payments totaling $ 850,000 , and we adjusted our accounts receivable reserve along with the corresponding accounts receivable balance such that the amount in excess of the settlement amount was written-off and the reserve associated with the unpaid portion of the settlement was no longer reserved for as of June 30, 2023. All remaining scheduled payments were received during fiscal 2024 and there are no outstanding amounts due from this former customer as of June 30, 2024. 

 Inventories 

 We operate primarily as a private-label contract manufacturer. We make products based upon anticipated demand or following receipt of customer specific purchase orders. From time to time, we make inventory for private-label contract manufacturing customers under a specific purchase order with delivery dates that may subsequently be rescheduled or canceled at the customer’s request. We value inventory at the lower of cost ( first -in, first -out) or net realizable value on an item-by-item basis, including costs for raw materials, labor and manufacturing overhead. We establish reserves equal to all or a portion of the related inventory to reflect situations in which the cost of the inventory is not expected to be recovered. This requires us to make estimates regarding the market value of our inventory, including an assessment for excess and obsolete inventory. Once we establish an inventory reserve in a fiscal period, the reduced inventory value is maintained until the inventory is sold or otherwise disposed of. In evaluating whether inventory is stated at the lower of cost or net realizable value, management considers such factors as the amount of inventory on hand, the estimated time required to sell such inventory, the remaining shelf life and efficacy, the foreseeable demand within a specified time horizon and current and expected market conditions. Based on this evaluation, we record adjustments to cost of goods sold to adjust inventory to its net realizable value.

 Property and Equipment 

 We state property and equipment at cost. Depreciation of property and equipment is provided using the straight-line method over their estimated useful lives, generally ranging from 1 to 39 years. We amortize leasehold improvements using the straight-line method over the shorter of the useful life of the improvement or the term of the lease. Maintenance and repairs are expensed as incurred. Significant expenditures that increase economic useful lives of property or equipment are capitalized and expensed over the useful life of such expenditure.

 Impairment of Long-Lived Assets 

 We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. During fiscal 2024 and 2023 , we recognized no impairment losses.

 Derivative Financial Instruments 

 We may use derivative financial instruments in the management of our foreign currency exchange risk inherent in our forecasted sales denominated in Euros, our long-term lease liability denominated in Swiss Francs and our exposure to interest rate fluctuations related to our term-note with Wells Fargo.

 We may hedge our foreign currency exposures by entering into offsetting forward exchange contracts. To the extent we use derivative financial instruments that meet the relevant criteria, we account for them as cash flow hedges. Foreign exchange derivative instruments that do not meet the criteria for cash flow hedge accounting are marked-to-market through the Consolidated Statements of Operations and Comprehensive (Loss) Income. Historically, our cash flow derivative instruments related to our Euro sales have met the criteria for hedge accounting, while our derivative instruments related to our long-term lease liability have not. 

 We recognize any unrealized gains and losses associated with derivative instruments accounted for as cash flow hedges in income in the period in which the underlying hedged transaction is realized. To the extent the derivative instrument is deemed ineffective we would recognize the resulting gain or loss in income at that time. As of June 30, 2024 , we held derivative contracts designated as cash flow hedges primarily to protect against the foreign exchange risks inherent in our forecasted sales of products at prices denominated in currencies other than the U.S. Dollar, which is primarily the Euro. As of June 30, 2024 , the notional amounts of our foreign exchange contracts were $ 34.0 million (€ 30.8 million). These contracts will mature over the next 15 months.

 As of June 30, 2024 , we held foreign currency contracts not designated as cash flow hedges primarily to protect against changes in valuation of our long-term lease liability. As of June 30, 2024 , the notional amounts of our foreign currency contracts not designated as cash flow hedges were $ 11.9 million (CHF 10.5 million). These contracts will mature in the first quarter of fiscal year 2025. 

 We are exposed to interest rate fluctuations related to our $ 10.0 million Term Note with Wells Fargo, which carries a variable interest rate of 1.80 % above the SOFR rolling 30 -day average. To manage our exposure to this variable rate, on August 23, 2021, we entered into a floored interest rate swap that fixes our all-in rate on this loan to 2.4 % for the first three years of the term loan.

 32 
 
 Table of Contents 
 
 Defined Benefit Pension Plan 

 We formerly sponsored a defined benefit pension plan. Effective June 21, 1999, we adopted an amendment to freeze benefit accruals to the participants. The plan obligation and related assets of the plan are presented in the notes to the consolidated financial statements. Plan assets, which consist primarily of marketable equity and debt instruments, are valued based upon third party market quotations. Independent actuaries, through the use of a number of assumptions, determine plan obligations and annual pension expense. Key assumptions in measuring the plan obligations include the discount rate and estimated future return on plan assets. In determining the discount rate, we use an average long-term bond yield. Asset returns are based on the historical returns of multiple asset classes to develop a risk free rate of return and risk premiums for each asset class. The overall rate for each asset class was developed by combining a long-term inflation component, the risk free rate of return and the associated risk premium. A weighted average rate is developed based on the overall rates and the plan’s asset allocation.

 Revenue Recognition 

 We record revenue based on a five -step model which includes: ( 1 ) identifying a contract with a customer; ( 2 ) identifying the performance obligations in the contract; ( 3 ) determining the transaction price; ( 4 ) allocating the transaction price among the performance obligations; and ( 5 ) recognizing revenue as each of the various performance obligations are satisfied.

 Revenue is measured as the net amount of consideration expected to be received in exchange for fulfilling one or more performance obligations. We identify purchase orders from customers as contracts. The amount of consideration expected to be received and revenue recognized includes estimates of variable consideration, including estimates for early payment discounts, volume rebates, and contractual discounts. Such estimates are calculated using historical averages adjusted for any expected changes due to current business conditions and experience. We review and update these estimates at the end of each reporting period and the impact of any adjustments are recognized in the period the adjustments are identified. In assessing whether collection of consideration from a customer is probable, we consider both the customer's ability and intent to pay the amount of consideration when it is due. Payment of invoices is due as specified in the underlying customer agreement, which is typically 30 days from the invoice date. Invoices are generally issued on the date of transfer of control of the products ordered to the customer.

 Revenue is recognized at the point in time that each of our performance obligations is fulfilled, and control of the ordered products is transferred to the customer. This transfer occurs when the product is shipped, or in some cases, when the product is delivered to the customer. We recognize revenue in certain circumstances before delivery to the customer has occurred (commonly referred to as bill-and-hold transactions). Products sold under bill-and-hold arrangements are recorded as revenue when risk of ownership has been transferred to the customer, but the product has not shipped due to a substantive reason, typically at the customer’s request. The product must be separately identified as belonging to the customer, ready for physical transfer to the customer, and we cannot have the ability to redirect the product to another customer.

 We provide early payment discounts to certain customers. Based on historical payment trends, we expect that these customers will take advantage of these early payment discounts. The cost of these discounts is reported as a reduction to the transaction price. If the actual discounts differ from those estimated, the difference is also reported as a change in the transaction price. We require prepayment from certain customers. We record any payments received in advance of contracts fulfillment as a contract liability and classified as customer deposits on the consolidated balance sheet.

 Contract liabilities and revenue recognized were as follows (in thousands):

 June 30, 2023 
 Additions 
 Revenue Recognized 
 Customer Refunds 
 June 30, 2024 
 
 Contract Liabilities (Customer Deposits)
 $ 317 $ 2,500 $ ( 2,515 ) $ — $ 302 

 June 30, 2022 
 Additions 
 Revenue Recognized 
 Customer Refunds 
 June 30, 2023 
 
 Contract Liabilities (Customer Deposits)
 $ 140 $ 317 $ ( 137 ) $ ( 3 ) $ 317 

 Except for product defects, no right of return exists on the sale of our products. We estimate returns based on historical experience and recognize a returns liability for any estimated returns. As of June 30, 2024 , we have $ 0 in our returns reserve.

 We currently own certain U.S. patents, and each patent’s corresponding foreign patent applications. All of these patents and patent rights relate to the ingredient known as beta-alanine marketed and sold under our CarnoSyn® and SR CarnoSyn® trade marks and our TriBysn™ tradename. We recorded beta-alanine raw material sales and royalty and licensing income as a component of revenue in the amount of $ 8.4 million during fiscal 2024 and $ 8.7 million during fiscal 2023 . These royalty income and raw material sale amounts resulted in royalty expense paid to the original patent holders from whom NAI acquired its patents and patent rights. We recognized royalty expense as a component of cost of goods sold in the amount of $ 0.3 million during fiscal 2024 and $ 0.3 million during fiscal 2023 . 

 Cost of Goods Sold 

 Cost of goods sold includes raw material, labor, manufacturing overhead, royalty expense, shipping, and customer related research and development costs.

 Shipping and Handling Costs 

 We include fees earned on the shipment of our products to customers in sales and include costs incurred on the shipment of product to customers in costs of goods sold.

 33 
 
 Table of Contents 
 
 Research and Development Costs 

 As part of the services we provide to our private-label contract manufacturing customers, we may perform, but are not obligated to perform, certain research and development activities related to the development or improvement of their products. While our customers typically do not pay directly for this service, the cost of this service is included as a component of the price we charge to manufacture and deliver their products. We also direct and participate in clinical research studies, often in collaboration with scientists and research institutions, to validate the benefits of a product and provide scientific support for product claims and marketing initiatives.

 Research and development costs are expensed when incurred. Our research and development expenses for the last two fiscal years ended June 30 were $ 1.9 million for fiscal 2024 and $ 2.1 million for fiscal 2023 . These costs are included in selling, general and administrative expenses and cost of goods sold.

 Advertising Costs 

 We expense the production costs of advertising the first time the advertising takes place. We incurred and expensed advertising costs in the amount of $ 0.3 million during the fiscal year ended June 30, 2024 and $ 0.7 million during fiscal 2023 . These costs are included in selling, general and administrative expenses.

 Income Taxes 

 To determine our annual provision for income taxes, we use an estimated annual effective tax rate that is based on annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions to which we are subject. We recognize interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 We record valuation allowances to reduce our deferred tax assets to an amount that we believe is more likely than not to be realized. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will ultimately be realized based on whether future taxable income will be generated during the periods in which those temporary differences become deductible. During the year ended June 30, 2024 , there was no change to our valuation allowance.

 Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are measured and recorded using enacted tax rates for each of the jurisdictions in which we operate, and adjusted using the tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income or expense in the period that includes the enactment date.

 We account for uncertain tax positions using the more-likely-than- not recognition threshold. It is our policy to establish reserves based on management’s assessment of exposure for certain positions taken in previously filed tax returns that may become payable upon audit by tax authorities. Our tax reserves are analyzed quarterly, and adjustments are made as events occur that we believe warrant adjustments to the reserves. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of June 30, 2024 and June 30, 2023 , we did not record any tax liabilities for uncertain tax positions.

 Stock-Based Compensation 

 We had an omnibus equity incentive plan that was approved by our Board of Directors effective October 15, 2009, and approved by our stockholders at the Annual Meeting of Stockholders held on November 30, 2009 (the "2009 Plan"). The 2009 Plan expired on October 15, 2019. The Board of Directors approved a new omnibus equity incentive plan that became effective January 1, 2021 ( the “2020 Plan”), which was approved by our stockholders at the Annual Meeting of Stockholders on December 4, 2020. Under the 2020 Plan, we may grant nonqualified and incentive stock options, restricted stock grants, restricted stock units, stock appreciation rights, and other stock-based awards to employees, non-employee directors and consultants.

 We estimate the fair value of stock option awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. Option valuation models require the use of highly subjective assumptions. Black-Scholes uses assumptions related to volatility, the risk-free interest rate, the dividend yield (which we assume to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities used in the model are based on the historical volatility of our stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect in the period of grant. The expected life of stock option grants is derived from historical experience. The fair value of restricted stock shares granted is based on the market price of our common stock on the date of grant. We amortize the estimated fair value of our stock awards to expense over the related vesting periods.

 We recognize forfeitures as they occur.

 Use of Estimates 

 Our management has made a number of estimates and assumptions relating to the reporting of assets and liabilities, revenue and expenses, and the disclosure of contingent assets and liabilities to prepare these consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP). Actual results could differ from those estimates and our assumptions may prove to be inaccurate.

 34 
 
 Table of Contents 
 
 Net (Loss) Income per Common Share 

 We compute basic net (loss) income per common share using the weighted average number of common shares outstanding during the year, and diluted net income per common share using the additional dilutive effect of all dilutive securities. The dilutive impact of stock options and restricted shares account for the additional weighted average shares of common stock outstanding for our diluted net income per common share computation. We calculated basic and diluted net (loss) income per common share as follows (in thousands, except per share data):

 For the Years Ended June 30, 
 
 2024 
 2023 
 
 Numerator 
 
 Net (loss) income
 $ ( 7,217 ) $ 2,522 

 Denominator 
 
 Basic weighted average common shares outstanding
 5,871 5,863 

 Dilutive effect of stock options and restricted stock shares
 — 14 

 Diluted weighted average common shares outstanding
 5,871 5,878 

 Basic net (loss) income per common share
 $ ( 1.23 ) $ 0.43 

 Diluted net (loss) income per common share
 $ ( 1.23 ) $ 0.43 

 We exclude the impact of restricted stock from the calculation of diluted net loss per common share in periods where we have a net loss or when their inclusion would be antidilutive. During the year ended June 30, 2024 , we excluded 232,574 shares of unvested restricted stock. For the year ended June 30, 2023 we excluded restricted stock totaling 60,497 , as their impact would have been anti-dilutive.

 Concentrations of Credit Risk 

 Financial instruments that subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We place our cash and cash equivalents with highly rated financial institutions. Credit risk with respect to receivables is primarily concentrated with our three largest customers, whose receivable balances collectively represented 72.6 % of gross accounts receivable at June 30, 2024 and 47.4 % at June 30, 2023 . 

 Additionally, amounts due related to our beta-alanine raw material sales were 4.4 % of gross accounts receivable at June 30, 2024 and 21.4 % of gross accounts receivable at June 30, 2023 . Concentrations of credit risk related to the remaining accounts receivable balances are limited due to the number of customers comprising our remaining customer base.

 B. Inventories 

 Inventories, net, consisted of the following at June 30 (in thousands):

 2024 
 
 2023 
 
 Raw materials
 
 $ 
 18,489 
 
 $ 
 20,946 
 
 Work in progress
 
 3,362 
 
 4,504 
 
 Finished goods
 
 3,038 
 
 4,928 
 
 Reserves
 
 ( 640 
 ) 
 
 ( 684 
 ) 
 
 $ 
 24,249 
 
 $ 
 29,694 
 
 C. Property and Equipment 

 Property and equipment consisted of the following at June 30 (dollars in thousands):

 Depreciable 
 
 Life 
 
 In Years 
 
 2024 
 
 2023 
 
 Land
 
 NA 
 
 $ 
 8,940 
 
 $ 
 8,940 
 
 Building and building improvements
 
 7 – 39 
 
 24,723 
 
 24,712 
 
 Machinery and equipment
 
 3 – 12 
 
 43,631 
 
 41,460 
 
 Office equipment and furniture
 
 3 – 5 
 
 6,765 
 
 6,522 
 
 Vehicles
 
 3 
 
 237 
 
 227 
 
 Leasehold improvements
 
 1 – 20 
 
 23,223 
 
 22,641 
 
 Total property and equipment
 
 107,519 
 
 104,502 
 
 Less: accumulated depreciation and amortization
 
 ( 55,308 
 ) 
 
 ( 50,661 
 ) 
 
 Property and equipment, net
 
 $ 
 52,211 
 
 $ 
 53,841 
 
 Depreciation and amortization expense was approximately $ 4.6 million in fiscal 2024 and $ 4.3 million in fiscal 2023 .

 35 
 
 Table of Contents 
 
 D. Leases 

 We currently lease our Vista, California and Lugano, Switzerland product manufacturing and support facilities. At the inception of a contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: ( 1 ) whether the contract involves the use of a distinct identified asset, ( 2 ) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period of the contract, and ( 3 ) whether we have the right to direct the use of the asset during such time period. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments.

 On July 18, 2023, we entered into a Fourth Amendment to the Lease of our Vista, California manufacturing facility. The Fourth Amendment extends the term of the Lease by an additional ten years and five months commencing April 1, 2024. The amended lease covering two buildings and approximately 162,000 square feet will result in an increase in base rent to $ 1.50 per square foot, after five free months of base rent beginning at the commencement of the extended term. NAI intends to construct substantial improvements to the facilities including but not limited to installation of an approximately $ 2.3 million solar electrical generating system on both buildings, and other substantial improvements. Pursuant to the Fourth Amendment, the Landlord will reimburse NAI for up to $ 1.1 million of these tenant improvements to the buildings. Our lease liability and right of use asset were both increased by approximately $ 25.9 million as a result of this lease extension effective on the date that the Fourth Amendment was executed.

 On January 26, 2024, we exercised the early termination of an apartment lease in Lugano, Switzerland. The early termination reduced the lease term by 9 years and 8 months thus ending on April 30, 2024. Our lease liability and right of use asset were both decreased by approximately $ 0.3 million as a result of the early termination of the lease agreement. On January 22, 2024, we entered into a lease for a new apartment in Lugano, Switzerland. This lease is for an initial term of 27 months beginning April 1, 2024 and ending on June 30, 2026. 

 Leases are classified as either finance leases or operating leases. A lease must be classified as a finance lease if any of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset, or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria. Substantially all our operating leases are comprised of payments for the use of manufacturing and office space. We have no leases classified as finance leases. As of June 30, 2024 , the weighted average remaining lease term for our operating leases was 9.5 years. The weighted average discount rate for our operating leases was 5.92 %. As of June 30, 2023 , the weighted average remaining lease term for our operating leases was 5.3 years and the weighted average discount rate was 4.12 %. The lease discount rate is determined as the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.

 For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

 The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, our secured incremental borrowing rate for the same term as the underlying lease. For our real estate and other operating leases, we use our secured incremental borrowing rate.

 Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Certain leases contain escalation clauses. Fixed escalation clauses are included in our calculation of right-of-use assets and operating lease liabilities. Escalation clauses based on the CPI (Consumer Price Index) are not included in our calculation of right-of-use assets and operating lease liabilities because they cannot be readily determined.

 Some of our manufacturing leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement and separated into lease and non-lease components based on the initial amount stated in the lease or standalone selling prices. Lease components are included in the measurement of the initial lease liability. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability.

 Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.

 We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset, lease liability, and the short-term lease cost for the years ended June 30, 2024 and 2023 was not material.

 Other information related to leases was as follows (in thousands) for the year ended June 30, 

 Supplemental Cash Flows Information 
 2024 
 2023 
 
 Cash paid for amounts included in the measurement of operating lease liabilities
 $ 2,966 $ 3,291 

 Net increase in operating lease liabilities and right-of-use assets due to lease remeasurement
 25,692 906 

 36 
 
 Table of Contents 
 
 E. Other Comprehensive (Loss) Income 

 Other comprehensive (loss) income (“OCL” and “OCI”) consisted of the following at June 30 (dollars in thousands):

 Year Ended June 30, 2024 
 
 Unrealized 
 
 Unrealized 
 
 Gains 
 
 Gains 
 
 (Losses) 
 
 (Losses) 
 
 Defined 
 
 on 
 
 on 
 
 Benefit 
 
 Cash Flow 
 
 Swap 
 
 Pension Plan 
 
 Hedges 
 
 Derivative 
 
 Total 
 
 Balance as of June 30, 2023
 
 $ 
 ( 380 
 ) 
 
 $ 
 ( 110 
 ) 
 
 $ 
 407 
 
 $ 
 ( 83 
 ) 
 
 OCI/OCL before reclassifications
 
 88 
 
 538 
 
 ( 422 
 ) 
 
 204 
 
 Amounts reclassified from OCI
 
 39 
 
 ( 92 
 ) 
 
 — 
 
 ( 53 
 ) 
 
 Tax effect of OCI activity
 
 ( 25 
 ) 
 
 ( 164 
 ) 
 
 99 
 
 ( 90 
 ) 
 
 Net current period OCI/OCL
 
 102 
 
 282 
 
 ( 323 
 ) 
 
 61 
 
 Balance as of June 30, 2024
 
 $ 
 ( 278 
 ) 
 
 $ 
 172 
 
 $ 
 84 
 
 $ 
 ( 22 
 ) 
 
 Year Ended June 30, 2023 
 
 Unrealized 
 
 Unrealized 
 
 Gains 
 
 Gains 
 
 (Losses) 
 
 (Losses) 
 
 Defined 
 
 on 
 
 on 
 
 Benefit 
 
 Cash Flow 
 
 Swap 
 
 Pension Plan 
 
 Hedges 
 
 Derivative 
 
 Total 
 
 Balance as of June 30, 2022
 
 $ 
 ( 444 
 ) 
 
 $ 
 1,795 
 
 $ 
 348 
 
 $ 
 1,699 
 
 OCI/OCL before reclassifications
 
 8 
 
 538 
 
 79 
 
 625 
 
 Amounts reclassified from OCI
 
 78 
 
 ( 3,086 
 ) 
 
 — 
 
 ( 3,008 
 ) 
 
 Tax effect of OCI activity
 
 ( 22 
 ) 
 
 643 
 
 ( 20 
 ) 
 
 601 
 
 Net current period OCI/OCL
 
 64 
 
 ( 1,905 
 ) 
 
 59 
 
 ( 1,782 
 ) 
 
 Balance as of June 30, 2023
 
 $ 
 ( 380 
 ) 
 
 $ 
 ( 110 
 ) 
 
 $ 
 407 
 
 $ 
 ( 83 
 ) 
 
 F. Debt 

 On May 24, 2021, we entered into a renewed credit facility with Wells Fargo Bank, N.A (“Wells Fargo”) to extend the maturity of our working line of credit from November 1, 2022 to May 24, 2024. That credit facility provided total lending capacity of up to $ 20.0 million and allowed us to use the credit facility for working capital as well as potential acquisitions. On August 18, 2021, we entered into an amendment of that credit facility with Wells Fargo. The amended credit facility added a $ 10.0 million term loan to the existing $ 20.0 million credit facility and permitted us to use the $10.0 million term loan as part of the $ 17.5 million purchase consideration for the acquisition of our new manufacturing and warehouse property in Carlsbad, California. The amended credit agreement also increased the allowed capital expenditures from $ 10.0 million to $ 15.0 million for fiscal 2022, (exclusive of the amount paid for the acquisition of the new Carlsbad property noted above). In addition, the revised credit notes reflected a change in the interest rate reference from London Interbank Offered Rate (LIBOR) to Secured Overnight Financing Rate (SOFR). The Credit Agreement was amended and a new Revolving Line of Credit Note and Security Agreement were entered into. A Term Note and real property security documents were added to secure the Term Note by the Carlsbad property.

 Subsequently we entered into a Second and Third Amendment that changed certain limits on our use of the line of credit.

 On December 31, 2023, we were not in compliance with certain financial covenants, including those related to net income requirements and the fixed charge coverage ratio. On February 13, 2024, we entered into a fourth amendment to our credit facility with Wells Fargo that waived all prior instances of non-compliance, decreased our total borrowing capacity on the line of credit to $ 12.5 million, increased the interest rate on borrowings under the line of credit to 2.25 % from 1.29 % above the daily simple SOFR rate, modified our continuing compliance requirements, and reduced the uses we can fund with the line of credit. Under the terms of the amended Credit Agreement, our new borrowing eligibility requirements including maintaining (i) a ratio of total liabilities to tangible net worth of not greater than 1.50 to 1.0 at any time; (ii) limits our losses to a decreasing amount over the next three quarters, with net income after taxes of not less than $ 1.00 by September 30, 2024; ( iii) a rolling four -quarter fixed charge coverage ratio not less than 1.25 to 1.0 as of December 31, 2024 and each quarter thereafter. The Fourth Amendment includes a limitation on the amount of capital expenditures that can be made in a given fiscal year, with such limitation set at $ 6.5 million, requires us to suspend share repurchase and dividend activity, and includes an availability reserve of 10 % that will be in place until we return to profitability. Any amounts outstanding under the line of credit bear interest at a fixed or fluctuating interest rate as elected by us from time to time. Any amounts outstanding under the line of credit must be paid in full on or before the maturity date which remains at May 23, 2025. Amounts outstanding that are subject to a fluctuating interest rate may be prepaid at any time without penalty. Amounts outstanding that are subject to a fixed interest rate may be prepaid at any time in minimum amounts of $ 100,000 , subject to a prepayment fee equal to the sum of the discounted monthly differences between payment under a fixed rate versus payment under the variable rate for each month from the month of prepayment through the month in which the then applicable fixed rate term matures. There is an unused commitment fee of 0.25 % required as part of the line of credit, and an origination fee of 1 % which we paid upon execution of the Fourth Amendment.

 37 
 
 Table of Contents 
 
 The Term Note used as part of the purchase consideration of our powder processing and warehouse property in Carlsbad, California referenced above, was for the original principal amount of $ 10.0 million, and is a seven -year term note with payments fully amortized based on a twenty-five year assumed term. Installment payments under this loan commenced October 1, 2021 and continue through August 1, 2028 with a final installment consisting of all remaining amounts due to be paid in full on September 1, 2028. Amounts outstanding on this note during the term of the agreement bear interest equal to 1.8 % above the SOFR rolling 30 -day average. In connection with our term loan, we entered into an interest rate swap with Wells Fargo that effectively fixes our interest rate on our term loan at 2.4 % for the first three years of the term of the note.

 Our obligations under the Credit Agreement are secured by our accounts receivable and other rights to payment, general intangibles, inventory, equipment and fixtures. We also have credit approval with Wells Fargo Bank, which allows us to hedge foreign currency exposures up to 30 months in the future. We also have credit approval with Bank of America which allows us to hedge foreign currency exposures up to 24 months in the future.

 During fiscal year 2024 , no interest expense was capitalized to building improvements as our facility in Carlsbad, California was placed into service in April 2023. As of June 30, 2023 , we capitalized $ 198,000 of interest expense to building improvements.

 As of
 June 30, 2024 , we had $
 9.2 million outstanding under the Term Note used
 August 2021 for the purchase of our Carlsbad, California powder processing and warehouse property. The future debt payments under the Term Note are as follows (in thousands):
 
 2025
 2026
 2027
 2028
 2029
 Total
 
 Future Debt Payments
 $ 296 $ 305 $ 315 $ 325 $ 7,988 $ 9,229 

 On June 30, 2024 , we were in compliance with all of the financial and other covenants required under the Amended Credit Agreement. We anticipate we will not be able to comply with all of the covenants required under the Amended Credit Agreement in the first half of fiscal 2025. We have advised the lender and are currently negotiating a potential revised credit facility or waiver. There can be no assurance we will be able to successfully complete the negotiation of a revised credit facility, or what the differences in amount, cost and other factors may be.

 As of June 30, 2024 , we had $ 3.4 million outstanding on our credit facility with Wells Fargo Bank. Our available borrowing capacity under the amended terms of our amended credit facility was $ 12.0 million as of June 30, 2024 .

 G. Income Taxes 

 During fiscal 2024 , we recorded U.S.-based domestic tax benefit of $ 2.2 million and negligible foreign tax benefit. During fiscal 2023 , we recorded U.S.-based domestic tax expense of $ 0.8 million and foreign tax expense of $ 0.2 million.

 The following is a geographical breakdown of (loss) income before income taxes (in thousands):

 2024 
 2023 
 
 United States
 $ ( 9,046 ) $ 2,588 

 Foreign
 ( 418 ) 967 

 Total (loss) income before income taxes
 $ ( 9,464 ) $ 3,555 

 The (benefit) provision for income taxes for the years ended June 30 consisted of the following (in thousands):

 2024 
 2023 
 
 Current:
 
 Federal
 $ ( 55 ) $ 843 

 State
 41 211 

 Foreign
 66 221 

 52 1,275 

 Deferred:
 
 Federal
 ( 2,007 ) ( 246 ) 

 State
 ( 223 ) 4 

 Foreign
 ( 69 ) — 

 ( 2,299 ) ( 242 ) 

 Total (benefit) provision for income taxes
 $ ( 2,247 ) $ 1,033 

 38 
 
 Table of Contents 
 
 Net deferred tax assets and deferred tax liabilities as of June 30 were as follows (in thousands):

 2024 
 2023 
 
 Deferred tax assets:
 
 Inventory capitalization
 $ 279 $ 220 

 Inventory reserves
 148 164 

 Lease liability
 8,497 2,018 

 Net operating loss carry forward
 1,505 433 

 Accrued compensation
 140 166 

 Capitalized research and experimentation
 694 412 

 Accrued contingent fee
 207 219 

 Stock-based compensation
 129 81 

 Forward contracts
 — 56 

 Tax credit carry forward
 682 229 

 Pension liability
 67 103 

 Other, net
 215 88 

 Total gross deferred tax assets
 12,563 4,189 

 Deferred tax liabilities:
 
 Withholding taxes
 ( 134 ) ( 401 ) 

 Fixed assets
 ( 1,485 ) ( 1,451 ) 

 Forward contracts
 ( 54 ) — 

 Lease asset
 ( 7,694 ) ( 1,951 ) 

 Other, net
 ( 26 ) ( 31 ) 

 Deferred tax liabilities
 ( 9,393 ) ( 3,834 ) 

 Net deferred tax assets
 $ 3,170 $ 355 

 As of June 30, 2024, the Company had U.S. federal net operating loss carryforwards of $ 4.6 million which may be carried forward indefinitely. The Company has state net operating loss carryforwards of $ 6.6 million, which, if unutilized, will begin to expire beginning in fiscal year 2031. The Company also has foreign net operating loss carryforwards of $ 0.3 million, which, if unutilized, will begin to expire in fiscal year 2031. The Company has federal and state tax credits of $ 0.8 million, which, if unutilized, will begin to expire in fiscal year 2041. 

 Pursuant to Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), the annual use of the net operating loss carry forwards and research and development tax credits could be limited by any greater than 50% ownership change during any three -year testing period. We did not have any ownership changes that met this criterion during the fiscal years ended June 30, 2024 and June 30, 2023 .

 We are subject to taxation in the U.S., Switzerland and various state jurisdictions. Our tax years for the fiscal year ended June 30, 2019 and forward are subject to examination by the U.S. tax authorities. Our tax years for the fiscal years ended June 30, 2018 and forward are subject to examination by the state tax authorities. Our tax years for the fiscal year ended June 30, 2023 and forward are subject to assessment by the Swiss tax authorities.

 NAIE’s effective tax rate for the fiscal year ended June 30, 2024 for Swiss federal, cantonal and communal taxes is approximately 1 %. This rate is lower than our historical effective rate for NAIE because NAIE recognized a pre-tax loss and the calculated benefit for the year was mostly offset by a capital tax that is calculated based on net equity regardless of whether the company recognized a profit or not. 

 As part of the Tax Cuts and Jobs Act of 2017 (the Tax Act), we were required to recognize a one -time deemed repatriation transition tax during the fiscal year ended June 30, 2018 based on our total post- 1986 earnings and profits (E&P) from our Swiss subsidiary, NAIE. This accumulated E&P amount has historically been considered permanently reinvested thereby allowing us to defer recognizing any U.S. income tax on the amount. We no longer consider undistributed foreign earnings from NAIE as of December 31, 2017 as indefinitely reinvested. We consider earnings accumulated subsequent to December 31, 2017 as indefinitely reinvested.

 For tax years commencing on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017, also eliminates the ability to immediately deduct research and development costs. Instead, taxpayers are mandated to capitalize these expenses and amortize them over five years for research conducted within the United States and 15 years for research conducted abroad, as stipulated in IRC Section 174. There is ongoing consideration in Congress for legislation that may revoke or postpone this capitalization and amortization requirement; however, there is no guarantee that this provision will undergo repeal or any other form of modification. Should this requirement remain unchanged, it will result in a reduction of our tax deduction for research and development expenses in the forthcoming years. During fiscal 2024 , NAIE declared a dividend of $ 5.4 million to NAI, which was paid in the first quarter of fiscal 2025. During fiscal 2023 , NAIE declared and paid dividends to NAI in the amount of $ 14.7 million. These amounts are part of the undistributed earnings that we recorded a one -time deemed repatriation transition tax on in fiscal 2018 and therefore we did not recognize any additional tax on these dividends. However, as part of these dividends, we were required to pay a 5 % Swiss withholding tax totaling $ 0.3 million in fiscal 2024 and $ 0.7 million in fiscal 2023 which were also accrued for as part of the implementation of the Tax Act in fiscal 2018. 

 39 
 
 Table of Contents 
 
 A reconciliation of our income tax (benefit) provision computed by applying the statutory federal income tax rate of 21% for fiscal 2024 and for fiscal 2023 to net (loss) income before income taxes for the year ended June 30 is as follows (dollars in thousands):

 2024 
 2023 
 
 Income taxes computed at statutory federal income tax rate
 $ ( 2,033 ) $ 749 

 State income taxes, net of federal income tax expense
 ( 215 ) 90 

 Permanent differences
 ( 20 ) 8 

 Foreign tax rate differential
 131 18 

 Tax credits
 ( 170 ) ( 347 ) 

 Stock based compensation
 93 61 

 Global intangible low-taxed income (GILTI)
 — 355 

 Return to provision - differences
 ( 33 ) 99 

 Income tax (benefit) provision as reported
 $ ( 2,247 ) $ 1,033 

 Effective tax rate
 ( 23.7 )% 29.1 % 

 We expect our U.S. federal statutory rate to be 21 % for fiscal years going forward.

 H. Employee Benefit Plans 

 401 (k) Plan 

 We have a profit-sharing plan pursuant to Section 401 (k) of the Code, whereby participants may contribute a percentage of compensation not in excess of the maximum allowed under the Code. Effective January 1, 2022, all employees are eligible to participate in the plan the first of the month following 30 days of employment. Also effective, January 1, 2022, we match 100 % of the first 5 % of a participant’s compensation contributed to the plan under the 401 (k) plan. The total contributions under the plan charged to income from operations totaled $ 0.6 million for fiscal 2024 and $ 0.7 million for fiscal 2023 .

 Additionally, we have a discretionary profit-sharing plan pursuant to Section 401 (k) of the Code, whereby we may contribute an additional percentage of compensation. Employees are not required to contribute to the plan to receive the discretionary profit-sharing contribution. We did not make any discretionary profit-sharing contributions in fiscal 2024 or in fiscal 2023 . 

 We have a “Cafeteria Plan” pursuant to Section 125 of the Code, whereby health care benefits are provided for active employees through insurance companies. Substantially all active full-time employees are eligible for these benefits. We recognize the cost of providing these benefits by expensing the annual premiums, which are based on benefits paid during the year. The premiums expensed to results from operations for these benefits totaled $ 1.4 million for the fiscal year ended June 30, 2024 and $ 1.7 million for the fiscal year ended June 30, 2023 .

 Deferred Compensation Plan 

 Effective July 16, 2020, the Board of Directors approved and adopted a Non-Qualified Incentive Plan (the “Incentive Plan”). Pursuant to the Incentive Plan, the Human Resources Committee and the Board of Directors may make deferred cash payments or other cash awards (“Awards”) to directors, officers, employees and eligible consultants of NAI, (“Participants”). These Awards are made subject to conditions precedent that must be met before NAI is obligated to make the payment. The purpose of the Incentive Plan is to enhance the long-term stockholder value of NAI by providing the Human Resources Committee and the Board of Directors the ability to make deferred cash payments or other cash awards to encourage Participants to serve NAI or to remain in the service of NAI, or to assist NAI to achieve results determined by the Human Resources Committee or the Board of Directors to be in NAI's best interest.

 The Incentive Plan authorizes the Human Resources Committee or the Board of Directors to grant to, and administer, unsecured and deferred cash Awards to Participants and to subject each Award to whatever conditions are determined appropriate by the Human Resources Committee or the Board of Directors. The terms of each Award, including the amount and any conditions that must be met to be entitled to payment of the Award are set forth in an Award Agreement between each Participant and NAI. The Incentive Plan provides the Board of Directors with the discretion to set aside assets to fund the Incentive Plan although that has not been done to date.

 During the year ended June 30, 2024 , we granted a total of $ 0.9 million in deferred cash awards to members of our Board of Directors and certain key members of our management team. During the year ended June 30, 2023 , we granted a total of $ 0.6 million in deferred cash awards to members of our Board of Directors and certain key members of our management team. Each deferred cash award provides for three equal cash payments to the applicable Participant to be paid on the one year, two year, and three year anniversaries of the date of the grant of such Awards, (the “Award Date”); provided on the date of each payment (the “Payment Date”), the Participant has been since the Award Date, and continues to be through the Payment Date, a member of our Board of Directors or an employee of NAI. In the event a Participant ceases to be an employee of NAI or a member of our Board of Directors prior to any Payment Date, no further payments shall be made in connection with the Award.

 40 
 
 Table of Contents 
 
 Defined Benefit Pension Plan 

 We formerly sponsored a defined benefit pension plan, which provides retirement benefits to employees based generally on years of service and compensation during the last five years before retirement. Effective June 21, 1999, we adopted an amendment to freeze benefit accruals to the participants. Annually, we contribute an amount not less than the minimum funding requirements of the Employee Retirement Income Security Act of 1974 nor more than the maximum tax-deductible amount.

 Disclosure of Funded Status 

 The following table sets forth the defined benefit pension plan’s funded status and amount recognized in our consolidated balance sheets at June 30 (in thousands):

 2024 
 2023 
 
 Change in Benefit Obligation:
 
 Benefit obligation at beginning of year
 $ 1,364 $ 1,438 

 Interest cost 
 49 46 

 Actuarial loss
 ( 39 ) ( 29 ) 

 Benefits paid
 — ( 91 ) 

 Benefit obligation at end of year
 $ 1,374 $ 1,364 

 Change in Plan Assets:
 
 Fair value of plan assets at beginning of year
 $ 1,025 $ 1,094 

 Actual return on plan assets
 91 22 

 Employer contributions
 116 — 

 Benefits paid
 — ( 91 ) 

 Fair value of plan assets at end of year
 $ 1,232 $ 1,025 

 Reconciliation of Funded Status:
 
 Difference between benefit obligation and fair value of plan assets
 $ ( 142 ) $ ( 339 ) 

 Unrecognized net actuarial loss in accumulated other comprehensive income
 282 409 

 Net amount recognized
 $ 140 $ 70 

 Projected benefit obligation
 $ 1,374 $ 1,364 

 Accumulated benefit obligation
 $ 1,374 $ 1,364 

 Fair value of plan assets
 $ 1,232 $ 1,025 

 The weighted-average discount rate used for determining the projected benefit obligations for the defined benefit pension plan was 5.28 % for the year ended June 30, 2024 and 4.89 % during the year ended June 30, 2023 .

 Net Periodic Benefit Cost 

 The components included in the defined benefit pension plan’s net periodic benefit expense for the fiscal years ended June 30 were as follows (in thousands):

 2024 
 2023 
 
 Interest cost
 $ 49 $ 46 

 Expected return on plan assets 
 ( 42 ) ( 42 ) 

 Recognized actuarial loss
 39 50 

 Settlement loss
 - 27 

 Net periodic benefit expense
 $ 46 $ 81 

 In the fiscal year ended June 30, 2024 , we contributed $ 0.1 million to our defined benefit pension plan, and in the fiscal year ended June 30, 2023 , we did not contribute to the plan.

 The following is a summary of changes in plan assets and benefit obligations recognized in other comprehensive income (loss) (in thousands): 

 2024 
 2023 
 
 Net loss
 $ ( 88 ) $ ( 8 ) 

 Settlement loss
 — ( 28 ) 

 Amortization of net loss 
 ( 39 ) ( 50 ) 

 Total recognized in other comprehensive loss
 $ ( 127 ) $ ( 86 ) 

 Total recognized in net periodic benefit cost and other comprehensive loss
 $ ( 81 ) $ ( 5 ) 

 41 
 
 Table of Contents 
 
 The estimated net loss for the defined benefit pension plan that will be amortized from accumulated other comprehensive income into net periodic benefit cost over the next fiscal year is approximately $ 24,000 . We do not have any transition obligations or prior service costs recorded in accumulated other comprehensive income.

 The following benefit payments are expected to be paid (in thousands):

 2025
 $ 1,009 

 2026
 13 

 2027
 101 

 2028
 29 

 2029
 32 

 2030-2034
 199 

 Total benefit payments expected to be paid
 $ 1,383 

 The weighted-average rates used for the years ended June 30 in determining the defined benefit pension plan’s net pension costs, were as follows:

 2024 
 2023 
 
 Discount rate
 5.28 % 4.89 % 

 Expected long-term rate of return
 6.70 % 6.24 % 

 Compensation increase rate
 N/A N/A 

 Our expected rate of return is determined based on a methodology that considers historical returns of multiple classes analyzed to develop a risk-free real rate of return and risk premiums for each asset class. The overall rate for each asset class was developed by combining a long-term inflation component, the risk-free real rate of return, and the associated risk premium. A weighted average rate was developed based on those overall rates and the target asset allocation of the plan.

 Our defined benefit pension plan’s weighted average asset allocation at June 30 and weighted average target allocation were as follows:

 Target 
 
 2024 
 2023 
 Allocation 
 
 Equity securities
 72 % 64 % 53 % 

 Debt securities
 14 % 14 % 41 % 

 Commodities
 0 % 12 % 4 % 

 Cash alternatives
 14 % 10 % 2 % 

 100 % 100 % 100 % 

 The underlying basis of the investment strategy of our defined benefit pension plan is to ensure that pension funds are available to meet the plan’s benefit obligations when due. Our investment strategy is a long-term risk controlled approach using diversified investment options with relatively minimal exposure to volatile investment options like derivatives.

 The fair values by asset category of our defined benefit pension plan at June 30, 2024 were as follows (in thousands):

 Quoted 
 
 Prices in 
 
 Active 
 
 Markets for 
 Significant 
 Significant 
 
 Identical 
 Observable 
 Unobservable 
 
 Assets 
 Inputs 
 Inputs 
 
 Total 
 (Level 1) 
 (Level 2) 
 (Level 3) 
 
 Equity securities(1)
 $ 889 $ 889 $ — $ — 

 Debt securities(2)
 $ 173 $ 173 $ — $ — 

 Cash alternatives(3)
 $ 170 $ 170 $ — $ — 

 Total
 $ 1,232 $ 1,232 $ — $ — 

 ( 1 )
 This category is comprised of publicly traded funds of which 72 % are U.S. large-cap funds, 24 % emerging market funds, and 4 % non-U.S. developed market funds.
 
 ( 2 )
 This category is comprised of publicly traded funds, of which 77 % are U.S. fixed income funds and 23 % are corporate fixed income funds.
 
 ( 3 )
 This category is comprised of money market funds.
 
 42 
 
 Table of Contents 
 
 I. Stockholders ’ Equity 

 Treasury Stock 

 On September 18, 2020, the Board of Directors authorized a $ 2.0 million increase to our stock repurchase plan (“Repurchase Plan”), thus bringing the total authorized repurchase amount to $ 12.0 million. On March 12, 2021, the Board of Directors authorized an additional $ 3.0 million increase to the Repurchase Plan, thus bringing the total authorized repurchase amount to $ 15.0 million. On January 14, 2022, the Board of Directors authorized an additional $ 3.0 million increase to the Repurchase Plan, thus bringing the total authorized repurchase amount to $ 18.0 million. Under the Repurchase Plan, we may, from time to time, purchase shares of our common stock, depending upon market conditions, in open market or privately negotiated transactions. The Fourth Amendment to the Credit Agreement with Wells Fargo effective February 13, 2024, currently prohibits most stock repurchases (see Note F). As a result, until that restriction is modified or removed, we do not intend to purchase our shares other than our longstanding practice of purchasing shares from our employees in exchange for paying the employees’ withholding tax requirements upon vesting of restricted stock held by the employee.

 Treasury Stock repurchases for the year ended June 30, 2024 were as follows:

 Shares 
 
 Average Cost 
 
 Total Cost (in thousands) 
 
 Shares purchased under Repurchase Plan
 
 — 
 
 $ 
 — 
 
 $ 
 — 
 
 Shares acquired from employees for restricted stock vesting
 
 37,128 
 
 5.96 
 
 221 
 
 Total
 
 37,128 
 
 $ 
 221 
 
 Treasury Stock repurchases for the year ended June 30, 2023 were as follows:

 Shares 
 
 Average Cost 
 
 Total Cost (in thousands) 
 
 Shares purchased under Repurchase Plan
 
 140,812 
 
 $ 
 9.19 
 
 $ 
 1,294 
 
 Shares acquired from employees for restricted stock vesting
 
 23,587 
 
 8.86 
 
 209 
 
 Total
 
 164,399 
 
 $ 
 1,503 
 
 Treasury stock repurchase costs include commissions and fees.

 Shares acquired from employees for restricted stock vesting were returned to us by the related employees and in return we paid each employee’s required tax withholding resulting from the vesting of restricted shares. The valuation of the shares acquired and thereby the number of shares returned to us was calculated based on the closing share price on the date the shares vested.

 Stock Incentive Plans 

 For the years ended June 30, 2024 and June 30, 2023 , the Company had no stock options outstanding.

 Restricted stock activity for the year ended June 30, 2024 was as follows:

 Weighted 
 
 Number of 
 
 Average Grant 
 
 Shares – 
 
 Date Fair 
 
 2020 Plan 
 
 Value 
 
 Nonvested at June 30, 2023
 
 223,682 
 
 $ 
 10.39 
 
 Granted
 
 166,500 
 
 $ 
 6.09 
 
 Vested
 
 ( 104,075 
 ) 
 
 $ 
 11.39 
 
 Forfeited
 
 ( 3,000 
 ) 
 
 $ 
 9.59 
 
 Nonvested at June 30, 2024
 
 283,107 
 
 $ 
 7.50 
 
 Available for grant at June 30, 2024
 
 182,877 
 
 43 
 
 Table of Contents 
 
 Restricted stock activity for the year ended June 30, 2023 was as follows:

 Weighted 
 
 Number of 
 
 Average Grant 
 
 Shares – 
 
 Date Fair 
 
 2009 Plan 
 
 Value 
 
 Nonvested at June 30, 2022
 
 1,666 
 
 $ 
 8.50 
 
 Granted
 
 — 
 
 $ 
 — 
 
 Vested
 
 ( 1,666 
 ) 
 
 $ 
 8.50 
 
 Forfeited
 
 — 
 
 $ 
 — 
 
 Nonvested at June 30, 2023
 
 — 
 
 $ 
 — 
 
 Available for grant at June 30, 2023
 
 — 
 
 Weighted 
 
 Number of 
 
 Average Grant 
 
 Shares – 
 
 Date Fair 
 
 2020 Plan 
 
 Value 
 
 Nonvested at June 30, 2022
 
 186,227 
 
 $ 
 12.56 
 
 Granted
 
 123,000 
 
 $ 
 8.79 
 
 Vested
 
 ( 71,146 
 ) 
 
 $ 
 13.04 
 
 Forfeited
 
 ( 14,399 
 ) 
 
 $ 
 11.69 
 
 Nonvested at June 30, 2023
 
 223,682 
 
 $ 
 10.39 
 
 Available for grant at June 30, 2023
 
 349,377 
 
 Restricted stock grants, granted to members of our Board of Directors and certain key members of our management team, vest over a period of years from the date of grant and the unvested shares cannot be sold or otherwise transferred and the right to receive dividends, if declared by our Board of Directors, is forfeitable until the shares become vested. The total remaining unrecognized compensation cost related to unvested restricted stock shares amounted to $ 1.7 million at June 30, 2024 and the weighted average remaining requisite service period of unvested restricted stock shares was 2.1 years.

 J. Commitments 

 We lease a total of approximately 162,000 square feet at our manufacturing facility in Vista, California from an unaffiliated third party under a non-cancelable operating lease. On July 31, 2013, we executed a third amendment to the lease for our manufacturing facility in Vista, California. As a result of this amendment, our facility lease had been extended through March 2024. On July 18, 2023, we entered into a fourth amendment to the lease of our Vista, California manufacturing facility. The fourth amendment extends the term of the lease by an additional ten years and five months commencing April 1, 2024 and includes an option to extend the lease through August 31, 2039. 

 NAIE leases facility space in Manno, Switzerland from two unaffiliated third parties. The leased spaces total approximately 125,000 square feet . We primarily use the facilities for manufacturing, packaging, warehousing and distributing nutritional supplement products for the European and Asian marketplaces. On July 1, 2019, NAIE extended the lease on its main manufacturing facility for an additional five years through June 30, 2024. On May 4, 2022, NAIE further extended the lease on its main manufacturing facility for a new term of ten years effective January 1, 2023 with a new expiration date of December 31, 2032, with an option to extend one year.

 On November 5, 2018, NAIE entered into a lease with Sofinol SA for approximately 2,870 square meters of commercial warehouse space in a building located on the property adjacent to the leasehold for the primary existing NAIE facility in Manno, Switzerland. NAIE uses the space primarily for raw material storage. The lease is for an initial five -year term commencing on January 1, 2019 and NAIE can terminate the lease with 12 months advance notice given on June 30th or December 31st each year of the initial term. At the end of the initial term the lease transfers to an indefinite tenancy at the same rental rate terminable by NAIE or the landlord upon 12 months' advance notice. This initial term of this lease ends on December 31, 2024 and as of June 30, 2024, we have not provided notification of terminating this lease, so the term automatically extended to December 31, 2025. 

 On January 26, 2024, we exercised the early termination of an apartment lease in Lugano, Switzerland. The early termination reduced the lease term by 9 years and 8 months thus ending on April 30, 2024. Our lease liability and Right of Use asset were both decreased by approximately $ 0.3 million as a result of the early termination of the lease agreement. On January 22, 2024, we entered into a lease for a new apartment in Lugano, Switzerland. This lease is for an initial term of 27 months beginning April 1, 2024 and ending on June 30, 2026. 

 Minimum rental commitments (exclusive of property tax, insurance and maintenance) under all non-cancelable operating leases with initial or remaining lease terms in excess of one year, including the lease agreements referred to above, are set forth below as of June 30, 2024 (in thousands): 

 There- 
 
 2025 
 2026 
 2027 
 2028 
 2029 
 after 
 Total 
 
 Gross minimum rental commitments
 $ 4,182 $ 4,617 $ 4,554 $ 4,682 $ 4,814 $ 24,918 $ 47,767 

 Rental expense totaled $ 5.4 million for the fiscal year ended June 30, 2024 and $ 3.3 million for the fiscal year ended June 30, 2023 .

 44 
 
 Table of Contents 
 
 K. Economic Dependency 

 We had substantial net sales to certain customers during the fiscal years ended June 30 shown in the following table. The loss of any of these customers, or a significant decline in sales or the growth rate of sales to these customers, or in their ability to make payments when due, could have a material adverse impact on our net sales and net operating results. Net sales to any one customer representing 10% or more of the respective year’s consolidated net sales were as follows (dollars in thousands):

 Fiscal 2024 
 
 Fiscal 2023 
 
 Customer 1
 
 $ 
 48,055 
 
 $ 
 48,066 
 
 Customer 2
 
 16,312 
 
 61,646 
 
 Customer 3
 
 12,941 
 
 (a) 
 
 $ 
 77,308 
 
 $ 
 109,712 
 
 (a)
 
 Sales were less than 10% of the respective period’s consolidated net sales. 
 
 Accounts receivable from these customers totaled $ 12.3 million at June 30, 2024 and $ 1.8 million at June 30, 2023 .

 We buy certain products, including beta-alanine, from a single supplier. The loss of this supplier or other raw material suppliers could have a material adverse impact on our net sales and net income. Raw material purchases from any one supplier representing 10% or more of the respective period’s total raw material purchases were as follows (dollars in thousands):

 Year ended June 30, 
 
 2024 
 
 2023 
 
 % of Total 
 
 % of Total 
 
 Raw Material 
 
 Raw 
 
 Raw Material 
 
 Raw 
 
 Purchases by 
 
 Material 
 
 Purchases by 
 
 Material 
 
 Supplier 
 
 Purchases 
 
 Supplier 
 
 Purchases 
 
 Supplier 1
 
 $ 
 11,624 
 
 23 
 % 
 
 $ 
 11,487 
 
 13 
 % 
 
 $ 
 11,624 
 
 23 
 % 
 
 $ 
 11,487 
 
 13 
 % 
 
 L. Derivatives and Hedging 

 We are exposed to gains and losses resulting from fluctuations in foreign currency exchange rates relating to forecasted product sales denominated in foreign currencies and to other transactions of NAIE, our foreign subsidiary. As part of our overall strategy to manage the level of exposure to the risk of fluctuations in foreign currency exchange rates, we may use foreign exchange contracts in the form of forward contracts. There can be no guarantee any such contracts, to the extent we enter into such contracts, will be effective hedges against our foreign currency exchange risk.

 During the year ended June 30, 2024 and prior, we entered into forward contracts designated as cash flow hedges primarily to protect against the foreign exchange risks inherent in our forecasted sales of products at prices denominated in currencies other than the U.S. dollar. These contracts are expected to be settled through September 2025. For derivative instruments that are designated and qualify as cash flow hedges, we record the effective portion of the gain or loss on the derivative in accumulated other comprehensive income (OCI) as a separate component of stockholders’ equity and subsequently reclassify these amounts into earnings in the period during which the hedged transaction is recognized in earnings.

 For foreign currency contracts designated as cash flow hedges, hedge effectiveness is measured using the spot rate. Changes in the spot-forward differential are excluded from the test of hedge effectiveness and are recorded currently in earnings as revenue. We measure effectiveness by comparing the cumulative change in the hedge contract with the cumulative change in the hedged item as well as ensuring the assumptions we made at hedge inception have not materially changed. No hedging relationships were terminated as a result of ineffective hedging for the years ended June 30, 2024 and June 30, 2023 .

 We monitor the probability of forecasted transactions as part of the hedge effectiveness testing on a quarterly basis.

 As of June 30, 2024 , the notional amounts of our foreign exchange contracts accounted for as cash flow hedges were $ 34.0 million (€ 30.8 million). As of June 30, 2024 , a net gain of approximately $ 0.2 million offset by approximately $ 0.1 million of deferred taxes, related to derivative instruments designated as cash flow hedges was recorded in OCI. As of June 30, 2023 , a net loss of approximately $ 0.2 million, offset by approximately $ 0.1 million of deferred taxes, related to derivative instruments designated as cash flow hedges was recorded in OCI. It is expected that $ 0.2 million of the gross gain as of June 30, 2024 , will be reclassified into earnings in the next 12 months along with the earnings effects of the related forecasted transactions.

 During the year ended June 30, 2024 , we recognized $ 0.8 million of net gains in OCI and reclassified $ 0.4 million of gains and forward point amortization from OCI to Net Sales. During the year ended June 30, 2023 , we recognized $ 0.5 million of net gains in OCI and reclassified $ 3.1 million of gains and forward point amortization from OCI to Net Sales.

 For foreign currency contracts not designated as cash flow hedges, changes in the fair value of the hedge are recorded directly to foreign exchange gain or loss in other income in an effort to offset the change in valuation of the underlying hedged item. During the year ended June 30, 2024 , we entered into forward contracts in order to hedge foreign exchange risk associated with our lease liability at NAIE, which is denominated in Swiss Francs (CHF). As of June 30, 2024 , the notional amounts of our foreign exchange contracts not designated as cash flow hedges were approximately $ 11.9 million (CHF 10.5 million).

 We are exposed to interest rate fluctuations related to our $ 10.0 million Term Note with Wells Fargo, which carries a variable interest rate of 1.80 % above the SOFR rolling 30 -day average. To manage our exposure to this variable rate, on August 23, 2021, we entered into a floored interest rate swap that fixes our all-in rate on this loan to 2.4 % for the first three years of the term loan. Fluctuations in the relation of our contractual swap rate to current market rates are recorded as an asset or liability with an offset to OCI at the end of each reporting period. Interest expense is adjusted for the difference between the actual SOFR spread and the swap contractual rate such that our effective interest expense for each period is equal to our hedged rate of 2.4%. 

 45 
 
 Table of Contents 
 
 M. Contingencies 

 From time to time, we become involved in various investigations, claims and legal proceedings that arise in the ordinary course of our business. These matters may relate to product liability, employment, intellectual property, tax, regulation, contract or other matters. The resolution of these matters as they arise will be subject to various uncertainties and, even if such claims are without merit, could result in the expenditure of significant financial and managerial resources. While unfavorable outcomes are possible, based on available information, we generally do not believe the resolution of these matters will result in a material adverse effect on our business, consolidated financial condition, or results of operations and the price of our common stock. However, a settlement payment or unfavorable outcome could adversely impact our results of operations. Our evaluation of the likely impact of these actions could change in the future and we could have unfavorable outcomes we do not expect.

 Israel-Hamas War 

 In October 2023, armed conflict escalated between Israel and Hamas. Management is monitoring the conflict in Israel and Gaza and any broader economic effects from the crisis. Israel accounts for a small portion of our global net sales, but we also source multiple raw materials that come from Israel. While we do not anticipate this conflict will have a significant impact on our net sales, we are currently communicating with the customers and suppliers that may be impacted by this conflict, and we are evaluating options for alternative ingredient sources and/or holding safety stock of impacted materials to limit the effect this conflict may have on our ability to obtain the ingredients sourced from this region. There are further concerns regarding consumer purchasing and consumption behavior, increases in global shipping expenses, greater volatility in foreign exchange and interest rates, and other unforeseen business disruptions due to the current global geopolitical tensions, including and relating to this conflict between Israel and Hamas and the continued conflict in Ukraine. We will continue to evaluate impacts of these conflicts on our customers, suppliers, employees, and operations.

 N. Segment Information 

 Our business consists of two segments for financial reporting purposes. The two segments are identified as (i) private-label contract manufacturing, which primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other health care products, and (ii) patent and trademark licensing, which primarily includes direct raw material sales and royalty income from our license and supply agreements associated with the sale and use of beta-alanine under our CarnoSyn® and SR CarnoSyn® trade names.

 We evaluate performance based on a number of factors. The primary performance measures for each segment are net sales and income or loss from operations before corporate allocations. Operating income or loss for each segment does not include corporate general and administrative expenses, interest expense and other miscellaneous income and expense items. Corporate general and administrative expenses include, but are not limited to human resources, corporate legal, finance, information technology, and other corporate level related expenses, which are not allocated to any segment. Transfers of raw materials between segments are recorded at cost. The accounting policies of our segments are the same as those described in the summary of significant accounting policies in Note A.

 Our operating results by business segment for the years ended June 30 were as follows (in thousands):

 2024 
 2023 
 
 Net Sales 
 
 Private-label contract manufacturing
 $ 105,358 $ 145,294 

 Patent and trademark licensing
 8,438 8,721 

 $ 113,796 $ 154,015 

 2024 
 2023 
 
 (Loss) Income from Operations 
 
 Private-label contract manufacturing
 $ ( 3,466 ) $ 9,488 

 Patent and trademark licensing
 3,319 3,021 

 (Loss) income from operations of reportable segments
 ( 147 ) 12,509 

 Corporate expenses not allocated to segments
 ( 8,387 ) ( 7,796 ) 

 $ ( 8,534 ) $ 4,713 

 2024 
 2023 
 
 Assets 
 
 Private-label contract manufacturing
 $ 127,786 $ 102,495 

 Patent and trademark licensing
 34,556 31,657 

 $ 162,342 $ 134,152 

 Our private-label contract manufacturing products are sold both in the U.S. and in markets outside the U.S., including Europe, Canada, Australia, New Zealand, Mexico and Asia. Our primary markets outside the U.S. are Europe and Asia. Our patent and trademark licensing activities are primarily based in the U.S.

 Net sales by geographic region, based on the customers’ location, for the two years ended June 30 were as follows (in thousands):

 2024 
 2023 
 
 United States
 $ 73,512 $ 109,277 

 Markets outside the United States
 40,284 44,738 

 Total net sales
 $ 113,796 $ 154,015 

 Products manufactured by NAIE accounted for 79 % of consolidated net sales in markets outside the U.S. in fiscal 2024 and in fiscal 2023 . No products manufactured by NAIE were sold in the U.S. during the fiscal years ended June 30, 2024 and 2023 .

 46 
 
 Table of Contents 
 
 Long-lived assets by geographic region, based on the location of the company or subsidiary at which they were located or made, for the two years ended June 30 were as follows (in thousands):

 2024 
 2023 
 
 United States
 $ 78,146 $ 53,536 

 Europe
 17,602 20,674 

 Total Long-Lived Assets
 $ 95,748 $ 74,210 

 Total assets by geographic region, based on the location of the company or subsidiary at which they were located or made, for the two years ended June 30 were as follows (in thousands):

 2024 
 2023 
 
 United States
 $ 118,878 $ 89,167 

 Europe
 43,464 44,985 

 Total Assets
 $ 162,342 $ 134,152 

 Capital expenditures by geographic region, based on the location of the company or subsidiary at which they were located or made, for the two years ended June 30 were as follows (in thousands):

 2024 
 2023 
 
 United States
 $ 2,793 $ 13,210 

 Europe
 224 314 

 Total Capital Expenditures
 $ 3,017 $ 13,524 

 47 
 
 Table of Contents 
 
 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 

 None.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.
NATURAL ALTERNATIVES INTERNATIONAL INC 10-K

Item 8. Financial Statements and Supplementary Data
